['DRUG', 'EFFECT', 'CLINICAL COMMENT', 'GANCICLOVIR', '\xe2\x86\x91 DIDANOSINE \xc2\xa0CONCENTRATION', 'IF THERE IS NO SUITABLE ALTERNATIVE TO GANCICLOVIR, THEN USE IN COMBINATION WITH DIDANOSINE DELAYED-RELEASE WITH CAUTION. MONITOR FOR DIDANOSINE-ASSOCIATED TOXICITY.', 'METHADONE', '\xe2\x86\x93 DIDANOSINE CONCENTRATION', 'IF COADMINISTRATION OF METHADONE AND DIDANOSINE IS NECESSARY, THE RECOMMENDED FORMULATION OF DIANOSINE IS DIDANOSINE DELAYED-RELEASE. PATIENTS SHOULD BE CLOSELY MONITORED FOR ADEQUATE CLINICAL RESPONSE WHEN DIDANOSINE DELAYED-RELEASE IS COADMINISTERED WITH METHADONE, INCLUDING MONITORING FOR CHANGES IN HIV RNA VIRAL LOAD. DO NOT COADMINISTER METHADONE WITH DIDANOSINE PEDIATRIC POWDER DUE TO SIGNIFICANT DECREASES IN DIDANOSINE CONCENTRATIONS.', 'NELFINAVIR', 'NO INTERACTION ONE HOUR AFTER DIDANOSINE', 'ADMINISTER NELFINAVIR ONE HOUR AFTER DIDANOSINE DELAYED-RELEASE.', 'TENOFOVIR DISOPROXIL FUMARATE', '\xe2\x86\x91 DIDANOSINE CONCENTRATION', 'A DOSE REDUCTION OF DIDANOSINE DELAYED-RELEASE CAPSULES TO THE FOLLOWING DOSAGE ONCE DAILY TAKEN TOGETHER WITH TENOFOVIR DISOPROXIL FUMARATE AND A LIGHT MEAL (400 KCALORIES OR LESS AND 20% FAT OR LESS) OR IN THE FASTED STATE IS RECOMMENDED. COADMINISTRATION OF DIDANOSINE WITH FOOD DECREASES DIDANOSINE CONCENTRATIONS. THUS, ALTHOUGH NOT STUDIED, IT IS POSSIBLE THAT COADMINISTRATION WITH HEAVIER MEALS COULD REDUCE DIDANOSINE CONCENTRATIONS FURTHER. \xe2\x80\xa2\xc2\xa0250 MG (ADULTS WEIGHING AT LEAST 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) \xe2\x80\xa2\xc2\xa0200 MG (ADULTS WEIGHING LESS THAN 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN PATIENTS SHOULD BE MONITORED FOR DIDANOSINE-ASSOCIATED TOXICITIES AND CLINICAL RESPONSE.', '\xe2\x86\x91 INDICATES INCREASE \xe2\x86\x93 INDICATES DECREASE']